Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Opportunities for Treg cell therapy for the treatment of human disease.

Tytuł:
Opportunities for Treg cell therapy for the treatment of human disease.
Autorzy:
Bluestone JA; Sonoma Biotherapeutics, South San Francisco, CA, United States.
McKenzie BS; Sonoma Biotherapeutics, South San Francisco, CA, United States.
Beilke J; Sonoma Biotherapeutics, South San Francisco, CA, United States.
Ramsdell F; Sonoma Biotherapeutics, South San Francisco, CA, United States.
Źródło:
Frontiers in immunology [Front Immunol] 2023 Apr 19; Vol. 14, pp. 1166135. Date of Electronic Publication: 2023 Apr 19 (Print Publication: 2023).
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:
T-Lymphocytes, Regulatory*
Immune System Diseases*/metabolism
Humans ; CD4-Positive T-Lymphocytes ; Immune Tolerance ; Immunosuppression Therapy ; Cytokines/metabolism
References:
Nat Immunol. 2003 Apr;4(4):337-42. (PMID: 12612581)
BMJ. 2020 Oct 21;371:m3734. (PMID: 33087345)
Science. 2011 Jan 21;331(6015):337-41. (PMID: 21205640)
Am J Transplant. 2019 Jan;19(1):62-76. (PMID: 29766641)
Front Immunol. 2013 Jun 19;4:152. (PMID: 23801990)
J Immunol. 2006 Nov 1;177(9):5852-60. (PMID: 17056509)
J Immunol. 1995 Aug 1;155(3):1151-64. (PMID: 7636184)
Front Immunol. 2021 Dec 23;12:783282. (PMID: 35003100)
PLoS One. 2008 Jul 23;3(7):e2740. (PMID: 18648532)
J Exp Med. 2012 Sep 24;209(10):1713-22, S1-19. (PMID: 22966003)
Front Immunol. 2020 Sep 23;11:565518. (PMID: 33072105)
Mucosal Immunol. 2014 Jan;7(1):6-19. (PMID: 24084775)
Front Immunol. 2020 Apr 15;11:611. (PMID: 32351504)
Science. 2003 Feb 14;299(5609):1057-61. (PMID: 12522256)
Front Immunol. 2021 Apr 01;12:648408. (PMID: 33868284)
Nature. 2022 Feb;602(7897):503-509. (PMID: 35110735)
Nat Genet. 2001 Jan;27(1):20-1. (PMID: 11137993)
Diabetes. 2012 Sep;61(9):2340-8. (PMID: 22721971)
Sci Rep. 2018 May 9;8(1):7428. (PMID: 29743501)
Sci Transl Med. 2022 Nov 2;14(669):eabo2628. (PMID: 36322627)
Immunol Rev. 2006 Aug;212:301-13. (PMID: 16903922)
Science. 2022 Dec 16;378(6625):eaba1624. (PMID: 36520915)
Blood Adv. 2021 Mar 9;5(5):1425-1436. (PMID: 33666654)
Nature. 2011 Sep 21;478(7368):250-4. (PMID: 21937990)
Annu Rev Immunol. 2016 May 20;34:609-33. (PMID: 27168246)
Annu Rev Immunol. 2020 Apr 26;38:541-566. (PMID: 32017635)
J Exp Med. 2004 Jun 7;199(11):1455-65. (PMID: 15184499)
Int J Mol Sci. 2023 Jan 16;24(2):. (PMID: 36675265)
Cytotherapy. 2023 Mar;25(3):245-253. (PMID: 36437190)
Sci Transl Med. 2015 Nov 25;7(315):315ra189. (PMID: 26606968)
Cell Physiol Biochem. 2017;43(6):2155-2169. (PMID: 29069643)
Mol Ther Methods Clin Dev. 2018 Jan 31;8:198-209. (PMID: 29552576)
JCI Insight. 2017 Oct 19;2(20):. (PMID: 29046484)
Blood. 2016 Feb 25;127(8):1044-51. (PMID: 26563133)
Science. 2021 Jul 30;373(6554):510-516. (PMID: 34326232)
Am J Transplant. 2017 Nov;17(11):2945-2954. (PMID: 28675676)
Cell Host Microbe. 2008 Jun 12;3(6):341-3. (PMID: 18541209)
J Immunol. 2013 Feb 1;190(3):1076-84. (PMID: 23277487)
Nat Med. 2009 Feb;15(2):192-9. (PMID: 19169263)
Front Immunol. 2018 May 15;9:1048. (PMID: 29868011)
Science. 1993 Feb 12;259(5097):974-7. (PMID: 8094901)
Front Immunol. 2021 Nov 18;12:744763. (PMID: 34867967)
BioDrugs. 2013 Dec;27(6):605-14. (PMID: 23813436)
Nat Immunol. 2003 Apr;4(4):330-6. (PMID: 12612578)
Front Immunol. 2012 Jan 12;2:98. (PMID: 22566887)
Cancer Gene Ther. 2021 Jun;28(6):581-589. (PMID: 33654227)
Front Immunol. 2022 May 16;13:893576. (PMID: 35651624)
Eur J Immunol. 2009 Apr;39(4):1108-17. (PMID: 19350586)
Nature. 1953 Oct 3;172(4379):603-6. (PMID: 13099277)
Immunol Rev. 2014 May;259(1):88-102. (PMID: 24712461)
Pediatr Diabetes. 2013 Aug;14(5):322-32. (PMID: 23627860)
JCI Insight. 2019 May 16;4(10):. (PMID: 31092732)
Nat Genet. 2001 Jan;27(1):68-73. (PMID: 11138001)
Science. 2010 Sep 24;329(5999):1667-71. (PMID: 20929851)
J Allergy Clin Immunol. 2018 Dec;142(6):1710-1718. (PMID: 30367909)
Gut. 2023 Jan;72(1):49-53. (PMID: 35428657)
Cell. 2015 Aug 27;162(5):1078-89. (PMID: 26317471)
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):228-235. (PMID: 30504315)
J Immunol. 2008 Apr 1;180(7):4366-70. (PMID: 18354156)
Immunol Rev. 2013 Sep;255(1):182-96. (PMID: 23947355)
Curr Top Microbiol Immunol. 2008;321:151-68. (PMID: 18727491)
Nat Immunol. 2014 Nov;15(11):1070-8. (PMID: 25263123)
Gastroenterology. 2012 Nov;143(5):1207-1217.e2. (PMID: 22885333)
Lancet. 2020 May 23;395(10237):1627-1639. (PMID: 32446407)
J Exp Med. 2012 Sep 24;209(10):1723-42, S1. (PMID: 22966001)
Nat Med. 2014 Jan;20(1):62-8. (PMID: 24362934)
Immunity. 2000 Apr;12(4):431-40. (PMID: 10795741)
Gut. 2016 Apr;65(4):584-94. (PMID: 25715355)
Cancer Immunol Res. 2022 May 3;10(5):581-596. (PMID: 35286392)
Am J Transplant. 2016 Jan;16(1):58-71. (PMID: 26414799)
Sci Rep. 2022 May 19;12(1):8348. (PMID: 35589917)
Cold Spring Harb Perspect Biol. 2012 Apr 01;4(4):a006908. (PMID: 22395097)
Neurol Neuroimmunol Neuroinflamm. 2018 May 18;5(4):e465. (PMID: 29845093)
Nat Med. 2008 Jan;14(1):88-92. (PMID: 18066074)
J Exp Med. 2002 Jul 15;196(2):255-60. (PMID: 12119350)
Transplantation. 1993 Feb;55(2):374-80. (PMID: 8434390)
Gastroenterology. 2008 Jun;134(7):2014-24. (PMID: 18424268)
Nat Immunol. 2016 Nov;17(11):1322-1333. (PMID: 27595233)
J Immunol. 2006 Dec 15;177(12):8338-47. (PMID: 17142730)
Arthritis Rheumatol. 2019 Mar;71(3):431-440. (PMID: 30277008)
BMJ Open. 2022 Apr 15;12(4):e061864. (PMID: 35428650)
Arthritis Rheum. 2005 Jul;52(7):2212-21. (PMID: 15986351)
Oncotarget. 2016 Feb 16;7(7):7563-77. (PMID: 26788992)
Immunology. 1970 May;18(5):723-37. (PMID: 4911896)
JCI Insight. 2021 Sep 22;6(18):. (PMID: 34324441)
Nat Rev Drug Discov. 2019 Oct;18(10):749-769. (PMID: 31541224)
J Immunol. 2015 Sep 15;195(6):2507-13. (PMID: 26342103)
Hepatology. 2016 Aug;64(2):632-43. (PMID: 26773713)
Ann Neurol. 2022 Aug;92(2):195-200. (PMID: 35445431)
Cells. 2021 May 10;10(5):. (PMID: 34068819)
Cell Immunol. 2020 Sep;355:104160. (PMID: 32711171)
Lab Invest. 1976 Jun;34(6):550-7. (PMID: 947081)
Front Immunol. 2020 Feb 03;10:3136. (PMID: 32117202)
Blood. 2016 Sep 22;128(12):1651-9. (PMID: 27506541)
Contributed Indexing:
Keywords: Foxp3; Treg; autoimmunity; immune regulation; immune tolerance
Substance Nomenclature:
0 (Cytokines)
Entry Date(s):
Date Created: 20230508 Date Completed: 20230509 Latest Revision: 20230509
Update Code:
20240105
PubMed Central ID:
PMC10154599
DOI:
10.3389/fimmu.2023.1166135
PMID:
37153574
Czasopismo naukowe
Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population can develop in the thymus and in the peripheral tissues of the immune system through the expression of an epigenetically stabilized transcription factor, FOXP3. Treg cells mediate their tolerogenic effects using multiple modes of action, including the production of inhibitory cytokines, cytokine starvation of T effector ( e . g ., IL-2), Teff suppression by metabolic disruption, and modulation of antigen-presenting cell maturation or function. These activities together result in the broad control of various immune cell subsets, leading to the suppression of cell activation/expansion and effector functions. Moreover, these cells can facilitate tissue repair to complement their suppressive effects. In recent years, there has been an effort to harness Treg cells as a new therapeutic approach to treat autoimmune and other immunological diseases and, importantly, to re-establish tolerance. Recent synthetic biological advances have enabled the cells to be genetically engineered to achieve tolerance and antigen-specific immune suppression by increasing their specific activity, stability, and efficacy. These cells are now being tested in clinical trials. In this review, we highlight both the advances and the challenges in this arena, focusing on the efforts to develop this new pillar of medicine to treat and cure a variety of diseases.
Competing Interests: All the authors are employed by Sonoma Biotherapeutics.
(Copyright © 2023 Bluestone, McKenzie, Beilke and Ramsdell.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies